基因工程在克服移植免疫排斥反应及诱导免疫耐受中的应用

被引:1
作者
孙祖玥
赵勇
机构
[1] 中国科学院动物研究所生物膜与膜生物工程国家重点实验室移植生物学研究组
[2] 中国科学院动物研究所生物膜与膜生物工程国家重点实验室移植生物学研究组 北京
[3] 北京
关键词
基因治疗; 免疫耐受; 移植排斥; 器官移植;
D O I
10.13523/j.cb.20050102
中图分类号
Q78 [基因工程(遗传工程)];
学科分类号
071007 ; 0836 ; 090102 ;
摘要
有效地控制慢性移植排斥反应和诱导移植免疫耐受是当今移植免疫学研究的热点。基因工程由于在克服移植免疫排斥反应和诱导免疫耐受中具有独特优势而倍受人们关注。然而,在临床应用基因治疗克服移植器官排斥之前,必须确定有效、安全的载体及适宜的靶基因。对该领域的新进展进行了简要综述。
引用
收藏
页码:6 / 9
页数:4
相关论文
共 15 条
[1]  
Ex vivo and systemictransfer of adenovirus-medialed CTLA4Ig gene cobined with a short course of FK506 therapy prolongs islet graft survival. Akamaru Y,Ito T,Uchikoshi F,et al. Transplant Immunology . 2003
[2]  
Gene therapy in transplantation. Hullett D A. The Journal of Heart and Lung Transplantation . 1996
[3]  
Calcium-and FK506-independent interaction between the immunophilin FKBP51 and calcineurin. Li T K,Baksh S,Cristillo A D,et al. Journal of Cellular Biochemistry . 2002
[4]  
Liver as an ideal target for gene therapy: expression of CTLA4Ig by retroviral gene transfer. Cheung S T,Tsui T Y,Wang W L,et al. Journal of Gastroenterology . 2002
[5]  
Xenotransplantation: the importance of the Galaphal, 3 Gal epitope in hyperacute vascular rejection. Joziasse D H,Oriol R. Biochimica et Biophysica Acta . 1999
[6]  
Transplantation[P]. 英国专利:GB9904281D0,1999-04-21
[7]  
Captopril enhances transforming growth factor (TGF) -betal expression in peripheral blood mononuclear cells: a mechanism independent from angotensin coverting enzyme inhibition. Di Paolo S,Schena A,Stallone G,et al. A study in cyclosporine-treated kidney-transplanted patients Transplantation . 2002
[8]  
Gene therapy of heart transplantation. Vassalli G. Revue Medicale de la Suisse Romande . 2002
[9]  
Induction of transgene-specific immunological tolerance in myeloablated nonhuman primates using lentivirally transduced CD34+ progenitor cells. Kung S K,An D S,Bonifacino A,et al. Molecular Therapy . 2003
[10]  
Nonviroal and viral gene transfer to the kidney in the context of transplantation. Benigni A,Tomasoni S,Lutz J,et al. Nephron . 2000